Bacillus clausii 088AE becomes the first VHP-listed B. clausii for dogs

Published: 5-Jun-2026

Specialty Enzymes & Probiotics announces that its spore-forming probiotic strain, Bacillus clausii 088AE, has been added to Health Canada's Veterinary Health Product (VHP) list for dogs, becoming the first and only Bacillus clausii strain to achieve this regulatory distinction

Health Canada's VHP review process requires precise strain identification, documented safety, manufacturing consistency and substantiated claims.

Bacillus clausii 088AE met every requirement, setting a new benchmark for spore-forming probiotics in companion animal health.

For pet supplement brands, the distinction delivers meaningful differentiation in an increasingly crowded probiotic market.

VHP-listed ingredients provide added regulatory credibility for retailers, veterinarians and ingredient-conscious pet parents seeking science-backed formulations.

"With FDA GRAS status and Health Canada NPN-approved claims, Bacillus clausii 088AE has already established a strong regulatory and scientific foundation in human health," said Reshma Rathi, Vice President of Specialty Enzymes & Probiotics.

"VHP recognition brings that same level of credibility to the pet space and gives formulators a truly differentiated, science-backed probiotic strain."

Bacillus clausii 088AE is also a foundational strain in ProbioSEB CSC3 Pet, Specialty's three-strain spore-forming probiotic blend developed for companion animal formulations for gut and immune health.

You may also like